Clareo Health | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BioNTech SE
With
Pfizer
Age
18–64
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participants 18 through 64 years of age (or the minimum age of consent in accordance with local regulations) at Visit 1.
Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
You may not be if
Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza.
Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (175 days) before study intervention administration.
Please refer to the study contact for further eligibility details
